Y. Uejima et al., SUPPRESSION OF HUMAN-IMMUNOGLOBULIN-E ANTIBODY-PRODUCTION BY A NEW NAPHTHALENE DERIVATIVE, Immunopharmacology, 30(2), 1995, pp. 167-176
A new naphthalene derivative, (E)-2-(7-(2-naphthyl)-6-heptenamide)benz
acid (TEI-8364) was assessed for its effect on interleukin (IL)-4- an
d anti-CD40 monoclonal antibody-induced immunoglobulin E (IgE) product
ion by cultured human lymphocytes. TEI-8364 preferentially suppressed
the production of IgE by peripheral blood mononuclear cells (PBMC) in
a dose-dependent manner, without inhibiting PBMC proliferation. In add
ition, TEI-8364, at a concentration of 10 mu M, completely inhibited I
L-4- and anti-CD40-induced IgE production by purified tonsillar B lymp
hocytes, suggesting that TEI-8364 affects B cells by interfering with
signals provided by IL-4 or through CD40 and IL-4. TEI-8364 also had a
profound inhibiting effect on the in vitro production of specific ant
ibody to a T cell-dependent antigen by PBMC from an immunized voluntee
r, cultured in the presence of antigen. Furthermore, TEI-8364 at a dos
e of 1 mg/mouse/day selectively inhibited IgE production by severe com
bined immunodeficiency mice engrafted with human PBMC, if the drug was
administered subcutaneously for five consecutive days. These findings
suggest that TEI-8364 is a potent therapeutic agent that may be usefu
l in the treatment of IgE-mediated allergic disorders.